This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
account_circleSign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

NICE guidance - Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Summary points from the guidance (1):

  • temozolomide, within its licensed indications, is recommended as an option for the treatment of newly diagnosed glioblastoma multiforme in patients with a World Health Organization (WHO) performance status of 0 or 1
  • carmustine implants, within their licensed indications, are recommended as an option for the treatment of newly diagnosed high-grade glioma only for patients in whom 90% or more of the tumour has been resected
  • treatment with carmustine implants should be provided only within specialist centres

Notes:

  • WHO performance status classification categorises patients as:
    • 0: able to carry out all normal activity without restriction
    • 1: restricted in strenuous activity but ambulatory and able to carry out light work
    • 2: ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours
    • 3: symptomatic and in a chair or in bed for greater than 50% of the day but not bedridden
    • 4: completely disabled; cannot carry out any self-care; totally confined to bed or chair

Reference:

  1. NICE (June 2007). Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.